MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro

Liu,Jingtian; Chen,Zongyou; Xiang,Jianbin; Gu,Xiaodong

doi:10.3892/ol.2018.8069

MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro

Authors:
- Jingtian Liu
- Zongyou Chen
- Jianbin Xiang
- Xiaodong Gu
View Affiliations

Affiliations: Department of Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China
Published online on: February 16, 2018 https://doi.org/10.3892/ol.2018.8069
Pages: 5561-5568
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer is one of the most common malignancies. Aberrant expressed microRNAs (miRNAs) have been demonstrated to have strong associations with colorectal cancer by repressing their targets. Therefore, miRNAs are thought to have signiﬁcant promise in the diagnosis and prognosis of colorectal cancer. Previous studies indicated that miR‑155 and collagen triple helix repeat containing 1 (CTHRC1) were both involved in pathogenesis of colorectal cancer, but the underlying mechanisms of miR‑155 and CTHRC1 are still unknown. The present study aimed to investigate the biological functions of miR‑155 and CTHRC1 in colorectal cancer. Reverse transcription‑quantitative polymerase chain reaction was used to examine miR‑155 and CTHRC1 expression levels. A dual‑luciferase reporter assay was applied to verify the target interaction between miR‑155 and CTHRC1. Proliferation, cell cycle, apoptosis, cell migration and invasion were measured using the MTT assay, flow cytometry and Transwell assays, respectively. Results showed that miR‑155 expression was decreased, but CTHRC1 expression was increased in colorectal cancer tissue and cell lines. Furthermore, it was demonstrated that miR‑155 negatively regulated CTHRC1. Additionally, miR‑155 overexpression suppressed cell proliferation, induced cell cycle arrest and promoted cell apoptosis, while an inhibitor of miR‑155 facilitated cell proliferation and cell cycle and repressed apoptosis. Transwell experiments indicated that miR‑155 inhibited the cell migratory and invasive abilities of HT‑29 cells, but miR‑155 inhibitor enhanced these abilities of HT‑29 cells. These results suggested that miR‑155 prevented colorectal cancer progression and metastasis via silencing CTHRC1 in vitro, which provides evidence for miR‑155 and CTHRC1 as a novel anti‑onco molecular target for the treatment of colorectal cancer in the future.

View Figures

View References

1	Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E and Rodriguez Yoldi MJ: Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 18(pii): E1972017. View Article : Google Scholar : PubMed/NCBI
2	Bolocan A, Ion D, Ciocan DN and Paduraru DN: Prognostic and predictive factors in colorectal cancer. Chirurgia (Bucur). 107:555–563. 2012.PubMed/NCBI
3	De Rosa M, Rega D, Costabile V, Duraturo F, Niglio A, Izzo P, Pace U and Delrio P: The biological complexity of colorectal cancer: Insights into biomarkers for early detection and personalized care. Therap Adv Gastroenterol. 9:861–886. 2016. View Article : Google Scholar : PubMed/NCBI
4	Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn WJ and Singh S: Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 15:665–674.e5. 2017. View Article : Google Scholar : PubMed/NCBI
5	Coppedè F, Lopomo A, Spisni R and Migliore L: Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol. 20:943–956. 2014. View Article : Google Scholar : PubMed/NCBI
6	Wang J, Du Y, Liu X, Cho WC and Yang Y: MicroRNAs as regulator of signaling networks in metastatic colon cancer. Biomed Res Int. 2015:8236202015.PubMed/NCBI
7	Berretta M, Alessandrini L, De Divitiis C, Nasti G, Lleshi A, Di Francia R, Facchini G, Cavaliere C, Buonerba C and Canzonieri V: Serum and tissue markers in colorectal cancer: State of art. Crit Rev Oncol Hematol. 111:103–116. 2017. View Article : Google Scholar : PubMed/NCBI
8	Lech G, Słotwiński R, Słodkowski M and Krasnodębski IW: Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol. 22:1745–1755. 2016. View Article : Google Scholar : PubMed/NCBI
9	Lech G, Slotwinski R and Krasnodebski IW: The role of tumor markers and biomarkers in colorectal cancer. Neoplasma. 61:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yamazaki N, Koga Y, Taniguchi H, Kojima M, Kanemitsu Y, Saito N and Matsumura Y: High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. Oncotarget. 8:6970–6983. 2017. View Article : Google Scholar : PubMed/NCBI
11	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010. View Article : Google Scholar : PubMed/NCBI
12	Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 96 Suppl:R40–R44. 2007.PubMed/NCBI
13	Ruan K, Fang X and Ouyang G: MicroRNAs: Novel regulators in the hallmarks of human cancer. Cancer Lett. 285:116–126. 2009. View Article : Google Scholar : PubMed/NCBI
14	Giannakakis A, Coukos G, Hatzigeorgiou A, Sandaltzopoulos R and Zhang L: miRNA genetic alterations in human cancers. Expert Opin Biol Ther. 7:1375–1386. 2007. View Article : Google Scholar : PubMed/NCBI
15	Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D, Forte S, De Maria R and Ricci-Vitiani L: Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 32:4806–4813. 2013. View Article : Google Scholar : PubMed/NCBI
16	Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, et al: Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 28:1385–1392. 2009. View Article : Google Scholar : PubMed/NCBI
17	Zhang G, Zhou H, Xiao H, Liu Z, Tian H and Zhou T: MicroRNA-92a functions as an oncogene in colorectal cancer by targeting PTEN. Dig Dis Sci. 59:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
18	Wan J, Xia L, Xu W and Lu N: Expression and function of miR-155 in diseases of the gastrointestinal tract. Int J Mol Sci. 17(pii): E7092016. View Article : Google Scholar : PubMed/NCBI
19	Hou Y, Wang J, Wang X, Shi S, Wang W and Chen Z: Appraising MicroRNA-155 as a noninvasive diagnostic biomarker for cancer detection: A meta-analysis. Medicine (Baltimore). 95:e24502016. View Article : Google Scholar : PubMed/NCBI
20	Yan L, Yu J, Tan F, Ye GT, Shen ZY, Liu H, Zhang Y, Wang JF, Zhu XJ and Li GX: SP1-mediated microRNA-520d-5p suppresses tumor growth and metastasis in colorectal cancer by targeting CTHRC1. Am J Cancer Res. 5:1447–1459. 2015.PubMed/NCBI
21	Wang JP: Chinese standard for the diagnosis and treatment of colorectal cancer (2010). Zhonghua Wei Chang Wai Ke Za Zhi. 14:1–4. 2011.(In Chinese). PubMed/NCBI
22	Binefa G, Rodriguez-Moranta F, Teule A and Medina-Hayas M: Colorectal cancer: From prevention to personalized medicine. World J Gastroenterol. 20:6786–6808. 2014. View Article : Google Scholar : PubMed/NCBI
23	Sideris M and Papagrigoriadis S: Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer Res. 34:2061–2068. 2014.PubMed/NCBI
24	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
25	Moridikia A, Mirzaei H, Sahebkar A and Salimian J: MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer. J Cell Physiol. 233:901–913. 2018. View Article : Google Scholar : PubMed/NCBI
26	He B, Gao SQ, Huang LD, Huang YH, Zhang QY, Zhou MT, Shi HQ, Song QT and Shan YF: MicroRNA-155 promotes the proliferation and invasion abilities of colon cancer cells by targeting quaking. Mol Med Rep. 11:2355–2359. 2015. View Article : Google Scholar : PubMed/NCBI
27	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
28	Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar : PubMed/NCBI
29	He Z, Yu L, Luo S, Li M, Li J, Li Q, Sun Y and Wang C: miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4. BMC Cancer. 17:1402017. View Article : Google Scholar : PubMed/NCBI
30	Tang L, Dai DL, Su M, Martinka M, Li G and Zhou Y: Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res. 12:3716–3722. 2006. View Article : Google Scholar : PubMed/NCBI